Ornim is a commercial-stage medical-technology company based in Kfar Saba, Israel, that focuses on clinical research, development and distribution of devices for tissue and cerebral blood flow and perfusion. Its FDA-cleared lead product, the c-FLOW™, is a non-invasive bedside monitor that provides real-time blood flow and perfusion measurements to the brain and other vital tissues. The c-FLOW™ is based on Ornim’s proprietary UTLight™ technology, which combines near-infrared light with ultrasound pulses, and has been clinically validated to measure cerebral and muscle tissue blood-flow changes. The company is led by president and CEO Israel Schreiber. Ornim intends to use new funds to accelerate U.S. commercial expansion and to obtain China Food and Drug Administration clearance for the c-FLOW™, with commercialization in China targeted for the second half of 2017 upon clearance. Ornim Medical develops non-invasive patient monitoring solutions for cerebral and tissue blood flow based on its patented UTLight™ technology. Its primary products are the CerOx™ and c-FLOW™ devices, intended for use in operating rooms, neuro-critical care and intensive care units, recovery rooms, and emergency rooms. The company says it plans future use in ambulances and MediVac. Ornim employs about 30 professionals including doctors, physicists, bio-engineers and researchers. Led by CEO Israel Schreiber, the company is advancing product development and international marketing efforts. The article reports a completed funding round to support those goals. Ornim develops the CerOx™ monitor, an FDA-cleared and CE-marked device that uses near-infrared spectroscopy combined with ultrasound to continuously and non-invasively measure regional hemoglobin oxygen saturation and microcirculation blood flow in tandem. The CerOx is designed for adult patients and intended for use across clinical settings including the operating room and intensive care unit. Ornim expects the combined measurement of oxygen saturation and blood flow to be essential during procedures under general anesthesia, for monitoring brain-injured patients, and during resuscitation. The company plans to launch the CerOx monitor in the U.S. and European markets within the next 18 months. Proceeds from the recent financing will fund further product development, clinical studies, and international marketing and commercialization.

Total raised

$50M

Funding rounds

3

Latest round

Series C

Latest activity

Aug 2016